Document is current

Article History

Received: 5 May 2025

Accepted: 27 September 2025

First Online: 10 December 2025

Declarations

:

: As this was non-clinical, non-interventional market research, it was exempt from Clinical Research Ethics Committee or Independent Review Board approval, per the European Pharmaceutical Market Research Association 2024 code of conduct.

: AMC reports personal fees including grants, speaker honoraria, consultancy or advisory fees, and/or research support and other from ALK-Abelló, AstraZeneca, Bencard Allergie, European Institute of Education and Technology (EIT Health), Federal Ministry of Education and Research (Germany), GSK, Hippo Dx, LETI, Novartis, Regeneron, Roche, Sanofi, Technical University of Munich from Allergopharma, Thermo Fisher Scientific, and Zeller.EC reports personal fees including honoraria, consulting, and lecture fees from AstraZeneca, GSK, Neopharma Gentili, NOOS, and Sanofi.PWH reports personal fees including unrestricted research grants and lecture honoraria from ALK, GSK, Novartis, Regeneron, Sanofi, and Viatris.NH is employed by, and holds financial equities, in GSK.BV reports personal fees including honoraria, consulting, and lecture fees from Amplifon, Collin, GSK, Medtronic, Mylan, and Sanofi.VH reports consultancy and speaker fees from AstraZeneca, ALK, Celltrion, GSK, and Sanofi.CJ has no conflicts of interest to declare.JM is or has been a member of national and international scientific advisory boards, received fees for lectures and grants for research projects or clinical trials from Almirall, AstraZeneca, GSK, LETI, Lilly, Menarini, MSD, NOUCOR/Uriach Group, Novartis, OptiNose, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB Pharma, and Viatris/MEDA Pharma.